Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
University of Technology Sydney · UNSW Sydney · +3 more institutions
Abstract
The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and high manufacturing cost associated with current ex vivo CAR T cell therapy products, alternative strategies to produce CAR T cells directly in the body have been developed in recent years. These strategies involve the direct infusion of CAR genes via engineered nanocarriers or viral vectors to generate CAR T cells in situ. This review offers a comprehensive overview of recent advancements in the development of T cell-targeted CAR generation in situ. Additionally, it identifies the challenges associated with in vivo CAR T method and potential…
Citation impact
- FWCI
- 33.51
- Percentile
- 100%
- References
- 172
Authors
5- TAThuỳ Anh Bùi
University of Technology Sydney, UNSW Sydney, Ingham Institute
- HMHaoqi Mei
University of Technology Sydney
- RSRui Sang
UNSW Sydney
- DGDavid Gallego‐Ortega
University of Technology Sydney, Garvan Institute of Medical Research, UNSW Sydney, The Kinghorn Cancer Centre
- WDWei DengCorresponding
University of Technology Sydney, UNSW Sydney
Topics & keywords
- Medicine
- Cancer
- In vivo
- Cancer research
- Bioinformatics
- Oncology
- Biology
- Internal medicine